Advanced search
1 file | 401.75 KB Add to list

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin

(2018) LIVER INTERNATIONAL. 38(9). p.1571-1575
Author
Organization
Abstract
Background & Aims: Some individuals with hepatitis C virus infection treated with direct-acting antivirals require ribavirin to maximize sustained virological response rates. We describe the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Methods: We performed a post hoc analysis of patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 or 24 weeks in six phase 3 trials. Multivariate stepwise logistic regression models assessed predictors associated with ribavirin dose adjustments and with developing anaemia. Results: Of 1548 patients, 100 (6.5%) modified ribavirin dose due to haemoglobin declines, of which 99% achieved sustained virological response at 12 weeks post-treatment. Median time to first ribavirin dose reduction was 37 days. Low baseline haemoglobin was significantly associated with an increased risk of requiring ribavirin dose modification (odds ratio: 0.618 [0.518, 0.738]; P < .001) and developing anaemia (odds ratio: 0.379 [0.243, 0.593]; P < .001). Conclusions: Ribavirin dose reductions were infrequent, occurred early in treatment, and did not impact sustained virological response at 12 weeks post-treatment. Patients with low baseline haemoglobin should be monitored for on-treatment anaemia.
Keywords
CHRONIC HEPATITIS-C, TREATMENT-EXPERIENCED PATIENTS, VIRUS-INFECTION, PLUS RIBAVIRIN, ABT-450/R-OMBITASVIR, THERAPY, ANEMIA, CIRRHOSIS, COMBINATION, SOFOSBUVIR, anaemia, dasabuvir, ombitasvir, paritaprevir, ribavirin

Downloads

  • Feld et al-2018-Liver International.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 401.75 KB

Citation

Please use this url to cite or link to this publication:

MLA
Feld, Jordan J, David E Bernstein, Ziad Younes, et al. “Ribavirin Dose Management in HCV Patients Receiving Ombitasvir/paritaprevir/ritonavir and Dasabuvir with Ribavirin.” LIVER INTERNATIONAL 38.9 (2018): 1571–1575. Print.
APA
Feld, J. J., Bernstein, D. E., Younes, Z., Van Vlierberghe, H., Larsen, L., Tatsch, F., & Ferenci, P. (2018). Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. LIVER INTERNATIONAL, 38(9), 1571–1575.
Chicago author-date
Feld, Jordan J, David E Bernstein, Ziad Younes, Hans Van Vlierberghe, Lois Larsen, Fernando Tatsch, and Peter Ferenci. 2018. “Ribavirin Dose Management in HCV Patients Receiving Ombitasvir/paritaprevir/ritonavir and Dasabuvir with Ribavirin.” Liver International 38 (9): 1571–1575.
Chicago author-date (all authors)
Feld, Jordan J, David E Bernstein, Ziad Younes, Hans Van Vlierberghe, Lois Larsen, Fernando Tatsch, and Peter Ferenci. 2018. “Ribavirin Dose Management in HCV Patients Receiving Ombitasvir/paritaprevir/ritonavir and Dasabuvir with Ribavirin.” Liver International 38 (9): 1571–1575.
Vancouver
1.
Feld JJ, Bernstein DE, Younes Z, Van Vlierberghe H, Larsen L, Tatsch F, et al. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. LIVER INTERNATIONAL. 2018;38(9):1571–5.
IEEE
[1]
J. J. Feld et al., “Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin,” LIVER INTERNATIONAL, vol. 38, no. 9, pp. 1571–1575, 2018.
@article{8572866,
  abstract     = {Background & Aims: Some individuals with hepatitis C virus infection treated with direct-acting antivirals require ribavirin to maximize sustained virological response rates. We describe the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. 
Methods: We performed a post hoc analysis of patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 or 24 weeks in six phase 3 trials. Multivariate stepwise logistic regression models assessed predictors associated with ribavirin dose adjustments and with developing anaemia. 
Results: Of 1548 patients, 100 (6.5%) modified ribavirin dose due to haemoglobin declines, of which 99% achieved sustained virological response at 12 weeks post-treatment. Median time to first ribavirin dose reduction was 37 days. Low baseline haemoglobin was significantly associated with an increased risk of requiring ribavirin dose modification (odds ratio: 0.618 [0.518, 0.738]; P < .001) and developing anaemia (odds ratio: 0.379 [0.243, 0.593]; P < .001). 
Conclusions: Ribavirin dose reductions were infrequent, occurred early in treatment, and did not impact sustained virological response at 12 weeks post-treatment. Patients with low baseline haemoglobin should be monitored for on-treatment anaemia.},
  author       = {Feld, Jordan J and Bernstein, David E and Younes, Ziad and Van Vlierberghe, Hans and Larsen, Lois and Tatsch, Fernando and Ferenci, Peter},
  issn         = {1478-3223},
  journal      = {LIVER INTERNATIONAL},
  keywords     = {CHRONIC HEPATITIS-C,TREATMENT-EXPERIENCED PATIENTS,VIRUS-INFECTION,PLUS RIBAVIRIN,ABT-450/R-OMBITASVIR,THERAPY,ANEMIA,CIRRHOSIS,COMBINATION,SOFOSBUVIR,anaemia,dasabuvir,ombitasvir,paritaprevir,ribavirin},
  language     = {eng},
  number       = {9},
  pages        = {1571--1575},
  title        = {Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin},
  url          = {http://dx.doi.org/10.1111/liv.13708},
  volume       = {38},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: